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The three low-molecular-weight heparins (LMWHs) available in the United
States have been extensively evaluated for a wide array of indications.
Properties associated with one LMWH cannot be assumed to be the same as
those associated with another LMWH, as they are different pharmacologic
entities.  Therefore, therapeutic interchange of these agents is inappropriate.
The pharmacokinetic and pharmacodynamic differences among LMWHs can
be explained by comparing methods of preparation, molecular structures,
half-lives, antithrombin- and non-antithrombin-mediated actions, effect on
thrombus, and dosing interval.  The Food and Drug Administration-approved
indications and their respective levels of clinical evidence further differentiate
these agents.  A dichotomy in the results of clinical trials has been observed
with the LMWHs.  As the LMWHs are distinct compounds that each possess
unique pharmacokinetic and pharmacodynamic profiles, treatment decisions
should be based on the available safety and efficacy data for each LMWH.
Agents should be prescribed only for those indications for which they have
been shown to be effective and only at dosages that have been studied.
(Pharmacotherapy 2001;21(6 Pt 2):62S–70S)
Low-molecular-weight heparins (LMWHs) are
heterogeneous mixtures of sulfated glycosamino-
glycans with approximately one-third the
molecular weight of unfractionated heparin
(UFH).1 They have several therapeutic advantages
relative to UFH:  a more predictable anticoagulation
dose-response, improved subcutaneous bioavail-
ability, dose-independent clearance, longer bio-
logic half-life, lower frequency of thrombo-
cytopenia, and a reduced requirement for routine
laboratory monitoring.1, 2 Although all the
LMWHs share a similar mechanism of action,
their molecular weight distributions vary,
resulting in differences in their activity against
factor Xa and thrombin, their affinity for plasma
proteins (Table 1), and their plasma half-lives.2
Low-molecular-weight heparins have been
evaluated extensively as treatment for a wide
array of indications such as acute coronary
syndromes, deep vein thrombosis (DVT), and
pulmonary embolism (PE).  They also have been
studied for prevention of venous thrombo-
embolism in several high-risk populations.
Three LMWHs—dalteparin, enoxaparin, and
tinzaparin—are available in the United States.
Food and Drug Administration (FDA)-approved
indications for these agents are product specific.
Clinical evidence for various indications also
differs.  Nevertheless, many institutions claim
that these agents are therapeutically equivalent
and use them interchangeably.
In this article, dalteparin, enoxaparin, and
tinzaparin are compared and contrasted to
demonstrate that they are distinct pharmacologic
entities and should not be interchanged.
Pharmacokinetic and pharmacodynamic
differences are recognized by comparing the
following properties:  method of preparation,
molecular structure, half-lives, antithrombin- and
non-antithrombin-mediated actions, effect on
thrombus, and dosing interval.  The FDA-
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approval status and, most important, their
respective available levels of clinical evidence,
further differentiate these agents.
Method of Preparation
Low-molecular-weight heparins are depolymer-
ized porcine mucosal pharmaceutical grade
heparin preparations, manufactured through
distinct depolymerization processes (Table 2).3–6
Nitrous acid depolymerization is used to produce
dalteparin,3, 4 and benzylation followed by
alkaline depolymerization is used in enoxaparin.3, 5
Tinzaparin is made by enzymatic depolymer-
ization with heparinase.3, 6 The different
depolymerization processes induce distinct
changes to the heparin molecule, resulting in a
unique molecular structure (Figure 1).  Nitrous
acid depolymerization induces the formation of
anhydromannose (5-member ring) on the
dalteparin molecule.  In contrast, the processes
used for enoxaparin and tinzaparin induce the
introduction of a double bond at the end
group.3–7 In addition, each preparation is
thought to have different proportions of
antithrombin-binding regions as well as linkage
regions, which are critical for their anticoagulant
action.8
Molecular Structure and Half-Life
The distinct manufacturing processes lead to
the formation of a heterogeneous mixture of
polysaccharide chains of different lengths and
molecular weights (Table 3).1, 4–6, 9 Of the three
molecules, dalteparin has the largest mean
molecular weight (6000 daltons), tinzaparin is
somewhat smaller (4500 daltons), and
enoxaparin is the smallest (4200 daltons).1 In
addition, their anti-Xa activities and half-lives
differ.  Tinzaparin demonstrated the longest half-
life (111–234 min), followed by enoxaparin
(129–180 min), then dalteparin (119–139 min).1,
4–6, 9
Using prophylactic dosages, the pharmaco-
kinetic properties of dalteparin, enoxaparin, and
nadroparin were directly compared.10 The
plasma anti-Xa area under the concentration-time
curve (AUC) activities of dalteparin, enoxaparin,
and nadroparin were investigated at dosages
administered for prevention of DVT.  Enoxaparin
40 mg (4000 IU anti-Xa) achieved a statistically
significant larger AUC compared with both
dalteparin 5000 IU anti-Xa and nadroparin 3075
IU anti-Xa.  On the other hand, the AUC of
nadroparin was significantly higher compared
with dalteparin.
The plasma anti-Xa half-lives after prophylactic
dosages of dalteparin 5000 IU anti-Xa,
enoxaparin 4000 IU anti-Xa, and tinzaparin 50
IU/kg anti-Xa were compared.11 Enoxaparin
demonstrated the longest anti-Xa half-life
compared with both dalteparin and tinzaparin.
No statistical difference existed between the half-
lives of dalteparin and tinzaparin.  Other
differences among the LMWHs relate to the
inhibitory activities against factor Xa and
thrombin.  Enoxaparin has the highest anti-
Xa:IIa ratio, followed by tinzaparin, then
dalteparin.1, 6
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Table 1.  Biologic Consequences of Reduced Binding of LMWHs to Proteins and Cells1, 2
Binding Target Biologic Effects Clinical Consequence
Thrombin Reduced anti-IIa activity None known
Proteins Improved bioavailability, Effective when given by
predictable anticoagulant subcutaneous injection,
response monitoring of anticoagulant
effect usually unnecessary
Macrophages Renally cleared Longer plasma half-life, once-daily
subcutaneous treatment effective
Platelets Reduced frequency of Reduced frequency of heparin-
heparin-antibodies induced thrombocytopenia
Osteoblasts Reduced activation of osteoblasts Reduced frequency of osteopenia
and osteoporosis
Table 2.  Methods of Preparation of FDA-Approved Low-
Molecular-Weight Heparin Products3–6
Agent Method of Preparation
Dalteparin Nitrous acid depolymerization
Enoxaparin Benzylation and alkaline depolymerization
Tinzaparin Heparinase digestion
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Figure 1.  Molecular structures of dalteparin, enoxaparin, and tinzaparin.4–6
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Antithrombin- and Non-antithrombin-Mediated
Actions
In addition to antithrombin III-mediated
effects (anti-Xa and anti-IIa effects), LMWHs are
further differentiated based on recent recognition
that non-antithrombin III-mediated actions and
other cellular and vascular interactions
contribute to the therapeutic effect of LMWHs
(Table 4).12 Non-antithrombin III-mediated
actions include the release of tissue factor
pathway inhibitor (TFPI), suppression of von
Willebrand factor (vWF) release, interaction with
heparin cofactor II, inhibition of leukocyte
procoagulant actions, promotion of fibrinolysis,
and modulation of vascular endothelium.12
The LMWHs stimulate the release of TFPI from
the endothelium and enhance its inhibitory
activity against factor Xa.13 In one study,7 the
pattern of TFPI release was investigated in six
LMWHs (certoparin, dalteparin, enoxaparin,
nadroparin, tinzaparin, reviparin) after an
intravenous injection of LMWH 100 IU/kg anti-
Xa to primates.  Each LMWH displayed a
different release pattern of TFPI, with tinzaparin
having the highest TFPI release after intravenous
administration, followed by enoxaparin and
dalteparin.  In a similar study, the pattern of TFPI
release after subcutaneous injection of LMWH
100 IU/kg anti-Xa to primates was evaluated.  Of
the six LMWHs studied (certoparin, enoxaparin,
fraxiparin, nadroparin, tinzaparin, reviparin),
enoxaparin produced the highest concentration
of free TFPI.14
No large human studies clearly demonstrate
which LMWH agent releases the most TFPI.
Varying patterns of release could lead to different
degrees of anticoagulation.  Interestingly,
preliminary research suggests that TFPI displays
an antiangiogenic effect, thus explaining some of
the beneficial effect noted in cancer survival.  In
fact, evidence indicates that LMWHs inhibit
angiogenesis, which appears unrelated to the
anticoagulant effects of the heparin products.15
Because this biochemical difference may translate
into clinically important variations, the
physiologic role of TFPI requires additional
clinical investigations.
Recent clinical research found a correlation
between LMWHs and vWF release.  Von
Willebrand factor plays an important role in
hemostasis.  Secretion of vWF from endothelial
cells and platelets promotes platelet aggregation
and adhesion to the exposed vascular
subendothelium.16 In addition, vWF is involved
in the coagulation cascade by binding to factor
VIII, thereby preventing inactivation of factor
VIIIa by activated protein C and consequently
promoting factor Xa and factor IIa generation
through the intrinsic coagulation cascade.1, 16, 17
Von Willebrand factor is a marker of platelet
stimulation and adverse clinical outcomes.  It
appears that each LMWH demonstrates a
different effect on vWF release.  In a recent study,
the differing patterns of vWF release among
dalteparin, enoxaparin, and UFH were
demonstrated in patients after acute coronary
events.18 This difference is important due to a
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Table 3.  Properties of Low-Molecular-Weight Heparin Products1, 4–6, 9
Mean Molecular Weight Plasma Half-Life Anti-Xa:Anti-IIa
Agent (daltons) (min) Activity Ratio
Dalteparin 6000 119–139 2.7
Enoxaparin 4200 129–180 3.8
Tinzaparin 4500 111–234 2.8
Table 4.  Biologic Actions of Low-Molecular-Weight Heparins12
Antithrombin-Mediated Actions Non-antithrombin-Mediated Actions
Anti-Xa activity Release of tissue-factor-pathway inhibitor
Anti-IIa activity Suppression of von Willebrand factor release
Interaction with heparin cofactor II
Inhibition of leukocyte procoagulant actions
Promotion of fibrinolysis
Protein binding
Modulation of vascular endothelium
(receptor and nonreceptor mediated)
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direct correlation between the extent of vWF
release and clinical outcomes in patients with
acute coronary syndrome.  Patients with high
vWF release within the first 48 hours after a
coronary event had worse clinical outcomes than
those whose level was not as high.  Those
patients who experienced adverse clinical
outcomes such as death, myocardial infarction, or
the need for urgent revascularization had a 7-fold
higher vWF level than those who did not
experience these outcomes.19
Compared with UFH, vWF release was
statistically lower in patients treated with
enoxaparin.  On the other hand, patients
receiving dalteparin and UFH demonstrated
similar release of vWF.18 This distinct effect of
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Table 5.  FDA-Approved Indications for Low-Molecular-Weight Heparins4–6
FDA-Approved Indication Dalteparin Enoxaparin Tinzaparin
Prophylaxis
Total hip arthroplasty X X
Total knee arthroplasty X
General surgery X X
Medically ill X
Treatment
Acute coronary syndrome X X
DVT with or without PE in
conjunction with warfarin X
Inpatient DVT with or without PE X
Outpatient DVT X
DVT = deep vein thrombosis; PE = pulmonary embolism.
Table 6.  FDA-Approved and Non-FDA-Approved Dosages for Low-Molecular-Weight Heparins1, 4–6
Indications Enoxaparin Dalteparin Tinzaparin
Hip replacement surgery 30 mg s.c. q12h started 2500 IU s.c. given 2 hrs 50 IU/kg q24h started the
(prophylaxis) 12–24 hrs after surgerya before surgery, followed evening before surgery or
or 40 mg s.c. q24h started by 2500 IU s.c. the evening 12 hrs after surgery
12 hrs before surgerya; after surgery and at least
extended prophylaxis may 6 hrs after the first dose,
be given for up to 3 wksa then 5000 IU s.c. q24ha;
or 5000 IU s.c. q24h started
the evening before surgerya;
or 2500 IU s.c. started 4–8
hrs after surgery, then
5000 IU s.c. q24h
Knee replacement surgery 30 mg s.c. q12h started No data 50 IU/kg q24h started the
(prophylaxis) 12–24 hrs before surgerya evening before surgery or
12 hrs after surgery
Abdominal surgery 40 mg s.c. q24h started 2500 IU s.c. started 1–2 hrs 3500 IU s.c. started 1–2 hrs
(prophylaxis) 2 hrs before surgerya before surgery, then q24ha before surgery
Patients with malignancy:
5000 IU s.c. the evening
before surgery, then 5000 IU
s.c. q24ha; or 2500 IU s.c.
1–2 hrs before surgery, then
2500 IU 12 hrs after surgery,
followed by 5000 IU s.c. q24ha
DVT treatment 1 mg/kg s.c. q12ha 100 IU/kg s.c. q12h 175 IU/kg s.c. q24ha
(with or without PE) or 1.5 mg/kg s.c. q24hb or 200 IU/kg s.c. q24h
Unstable angina or 1 mg/kg s.c. q12h 120 IU/kg s.c. q12h No data
non-Q-wave MI
MI = myocardial infarction.
aFDA-approved dosage for indication.
bFDA-approved dosage for inpatient use.
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vWF might explain the dichotomy observed with
the LMWH trials in acute coronary syndrome.
Dalteparin failed to demonstrate superiority to
UFH in the Fragmin in Unstable Coronary Artery
Disease (FRIC) trial.20 In contrast, enoxaparin
was proven twice to be superior to UFH in both
the Efficacy and Safety of Subcutaneous
Enoxaparin in Unstable Angina and Non-Q-Wave
Myocardial Infarction (ESSENCE) and
Thrombolysis in Myocardial Infarction (TIMI)-
11B trials in the 30-day composite end points of
death, myocardial infarction, recurrent angina, or
urgent revascularization.21–23 Tinzaparin was not
tested in this patient population.  Short of having
a head-to-head trial testing their relative benefits,
these findings suggest that important differences
in efficacy exist among LMWHs in treating
coronary artery disease.
It has been mentioned that the methodology
used in the ESSENCE, FRIC, and TIMI 11B trials
varied, which could account for their relative
differences in efficacy.  It should be noted,
however, that the widely publicized theory of
difference in quality of dosing of UFH arms to
explain the outcomes from those trials was
recently refuted.  It was first believed that the
dosing of UFH in the comparative arm of the
enoxaparin trial was suboptimal since it did not
reach therapeutic activated partial thomboplastin
time (aPTT) in all patients at 24 hours.  Critics
theorized that if the patients in the UFH arm
achieved all therapeutic aPTTs within the first 24
hours, enoxaparin would have not demonstrated
superiority over UFH.  This theory was revoked
in a recent published study.  In fact, enoxaparin
was shown to improve outcomes compared with
UFH at any levels of aPTT achieved.24
Thrombus Formation
In a model of thrombus induced by the ligation
of the inferior vena cava in mice, the
antithrombotic and antiinflammatory properties
of LMWHs during stasis-induced venous
thrombosis were compared.25 It was found that
enoxaparin prevented more thrombus formation
compared with dalteparin or placebo.  In
addition, less vein-wall neutrophils and total
inflammatory cells were present in the enoxaparin
group compared with dalteparin and placebo.
Tinzaparin was not tested in this animal model.25
FDA Status and Clinical Evidence
The FDA-approved indications for dalteparin,
enoxaparin, and tinzaparin in the U.S. market
differ (Table 5).4–6 In addition, all three LMWHs
have clinical evidence reported in the literature
for various treatment indications for which they
do not have FDA approval (Tables 6–9).1, 4–6, 26–28
Dalteparin has literature to support its use for the
treatment of DVT and PE.  Enoxaparin has safety
and efficacy data to support its use in multiple
trauma and neurosurgery.  There is evidence to
support tinzaparin for DVT prophylaxis in
general surgery, total hip arthroplasty, and total
knee arthroplasty.
Although published evidence can be found for
different clinical applications for each LMWH,
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Table 7.  Clinical Evidence in Venous Thromboembolism Prophylaxis1, 26
Indication Dalteparin Enoxaparin Tinzaparin
Hip replacement + + +
(postoperative)
Hip replacement + + –
(extended prophylaxis)
Knee replacement – + +
Orthopedic trauma – + –
General surgery + + +
Spinal cord injury – + +
Medically ill – + –
Neurosurgery – + –
Table 8.  Clinical Evidence in Venous Thromboembolism Treatment1, 27
Indication Dalteparin Enoxaparin Tinzaparin
Deep vein thrombosis + + +
Pulmonary embolism + + +
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one should be careful not to extrapolate the data
from one molecule to the other.  Clinicians and
formulary decision-makers should evaluate all
the available literature carefully before
recommending an agent and a specific dosing
regimen for a specific condition.  Clinicians
should refrain from using a LMWH for any
indication until the efficacy or safety of the agent
is objectively tested.
As an example, in a double-blind, randomized
clinical trial, 90 patients with hip fractures were
given dalteparin prophylactically for DVT.
Patients were randomized to receive dalteparin
2500 U before surgery, followed by UFH 5000 U
every 8 hours or dalteparin 5000 U after surgery
for 9 days.  Both groups had similar type and
extent of fracture and surgery.  A statistically
significant increase in the rate of PE on lung scan
and in the rate of DVT on venography was found
in the dalteparin group, suggesting that
subcutaneous UFH was superior to subcutaneous
dalteparin for DVT prophylaxis in this patient
population.29 Those findings should discourage a
clinician from using dalteparin in patients with
hip fractures.
When interpreting data about LMWHs,
variations in the design and methods of the
clinical trials must be considered.  In addition,
significant variations are noted in patient
selection, dosages of the agents, active treatment
duration, and the definition and assessment of
end points.  As a result, meta-analyses should be
interpreted with caution.  Several meta-analyses
have been performed that pooled the results of
controlled clinical trials comparing LMWHs and
intravenous UFH for the treatment of DVT.30–35
Clinical benefits were clearly achieved with
LMWH over UFH.  However, it was not clear
which LMWH agent was superior.
A recent meta-analysis compared five LMWH
products with UFH.31 The investigators stated,
“based on the pooled results there are no major
differences among preparations.  This suggests
that the use of any of the products in the dosages
evaluated in the trials is reasonable.”31 The
authors added, “however, this conclusion is
limited and must be tempered by the fact that the
comparison of LMWH products is indirect...it is
impossible to make definitive conclusions about
their relative safety and efficacy.”31 This analysis
therefore could not prove or refute any clinical
differences among the LMWHs.  Because the
LMWHs are not interchangeable and are different
entities, the strength of a meta-analytic approach
must be questioned, and only prospective, well-
designed, comparative trials could help answer if
the agents are clinically interchangeable.
Dosing Intervals and Practical Issues
The LMWHs require different dosing intervals
when treating DVT or PE.  Tinzaparin is safe and
effective as a once-daily agent for the treatment
of DVT and PE.36, 37 Enoxaparin also has been
shown to be safe and effective as a once- or
twice-daily agent.  There is cause for concern
about a trend toward more recurrent thrombo-
embolism when using once-daily enoxaparin
compared with twice-daily.  The patient
population of concern includes those who are
receiving treatment for DVT with or without PE
who have cancer or are obese.    Although the
absolute recurrence rate of venous thrombo-
embolism was nearly doubled in this patient
population, these differences did not reach
statistical significance.38
On the other hand, dalteparin is clearly best
used in a twice-daily regimen when used for the
treatment of DVT or PE.  In a randomized study,
dalteparin was evaluated in 140 patients with
iliofemoral DVT.  Patients were administered
dalteparin 200 IU/kg once/day versus 100 IU/kg
twice/day.  The once-daily treatment arm had a
statistically significant higher rate of sympto-
matic PE at 10 days; the twice-daily regimen
therefore is recommended for dalteparin.39
Practical issues should be considered when
selecting a LMWH.  Prefilled syringes are
available for treatment doses of enoxaparin, and
multidose vials are available for treatment doses
of dalteparin and tinzaparin.  Small amounts of
benzyl alcohol are present in the multidose
vials.4–6
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Table 9.  Clinical Evidence in Acute Coronary Syndrome Treatment1, 28
Indication Dalteparin Enoxaparin Tinzaparin
Unstable angina or non-ST
elevation myocardial infarction
Acute treatment, no intervention + + –
Acute treatment with intervention + + –
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Distinct Entities
Based on the chemical and pharmacologic
distinct attributes and the expanding clinical
roles of LMWHs, several organizations including
the FDA,40 the American College of Chest
Physicians,27 the International Cardiology
Forum,41 the American College of Cardiology,
and the American Heart Association42 published
statements supporting LMWHs to be distinct
pharmacologic entities.  The FDA stated,
“LMWH can not be used interchangeably, unit for
unit, with heparin, nor can one individual
LMWH be used interchangeably with another.”40
The American College of Chest Physicians stated,
“properties associated with one LMWH cannot be
extrapolated to a different LMWH.  Findings of
clinical trials apply only to the particular LMWH
evaluated and should not be generalized to the
LMWH at large.  Some of these LMWHs are
prepared by different methods of
depolymerization and differ to some extent in
their pharmacokinetic properties and
anticoagulant profile, they may not be clinically
interchangeable.”27 The American College of
Cardiology and the American Heart Association
noted that “although LMWHs share many
pharmacological similarities, they also vary in
important aspects, and it is important to consider
each drug individually rather than as members of
a class of interchangeable compounds.”42
It is a consensus from these groups that
properties associated with one LMWH cannot be
extrapolated to a different LMWH.  Treatment
decisions should be based on the available safety
and efficacy data for each LMWH.
Conclusion
The LMWHs are distinct compounds that
possess unique chemical, pharmacokinetic, and
pharmacodynamic profiles.  Each agent has
dissimilar antithrombotic activities, which are
reflected by antithrombin- (anti-Xa and anti-IIa
ratio) and non-antithrombin-mediated actions.
The LMWHs have shown divergent results in
clinical trials; it is not possible to draw
conclusions with regard to their relative clinical
efficacies.  As a result, several national
organizations support the concept that the
LMWHs are distinct entities and are not
therapeutically interchangeable.  In the absence
of comparative studies, clinical results of one
molecule should not be extrapolated to another.
An evidence-based approach is necessary for
selecting a LMWH.  Treatment decisions should
be based on the available safety and efficacy data
for each LMWH.  Agents should be prescribed
only for those indications for which they have
been shown to be effective and only at dosages
that have been studied. Each LMWH should be
considered unique until scientifically sound
comparative trials are performed.
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